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Mutations in calreticulin (CALR) are phenotypic drivers in the pathogenesis of 
myeloproliferative neoplasms (MPN). Mechanistic studies have demonstrated that mutant 
CALR binds to the thrombopoietin receptor MPL, and that the positive electrostatic charge of 
the mutant CALR C-terminus is required for mutant CALR- mediated activation of JAK-STAT 
signaling. Here we demonstrate that although binding between mutant CALR and MPL is 
required for mutant CALR to transform hematopoietic cells, binding alone is insufficient for 
cytokine independent growth. We further show that the threshold of positive charge in the 
mutant CALR C-terminus influences both binding of mutant CALR to MPL and activation of 
MPL signaling. We find that mutant CALR binds to the extra-cellular domain of MPL and that 
three tyrosine residues within the intracellular domain of MPL are required to activate 
signaling. With respect to mutant CALR function, we show that its lectin-dependent function is 
required for binding to MPL and for cytokine independent growth while its chaperone and 
polypeptide binding functionalities are dispensable. Together, our findings provide additional 




Recurrent mutations in calreticulin (CALR), an endoplasmic reticulum (ER) resident 
chaperone protein, represent the second most common mutation in patients with 
myeloproliferative neoplasms (MPN) after JAK2V617F (1-4). CALR mutations in MPN occur 
as a heterogeneous set of indel mutations in exon 9 of CALR that all result in a +1 base pair 
frameshift in the CALR reading frame (5, 6). Although the mutant CALR C- terminal 
alterations vary, all CALR mutations lead to loss of most of the C-terminal acidic domain and 
concomitant gain of a novel C-terminus consisting of 36 amino acids which are enriched for 
positively charged residues. Mechanistic studies have demonstrated that mutant CALR 
(CALRMUT) binds to the thromobopoietin receptor, MPL to activate the MPL-JAK-STAT 
signaling axis (7-10), and that the positive charge of the CALRMUT C- terminus is required to 
mediate this interaction (9). 
Several unanswered questions remain regarding the molecular and functional basis of 
CALRMUT oncogenic activity. In this report, we use a series of mutagenesis experiments to 
address some of these questions, focusing on the structural determinants of CALRMUT and 
MPL that are necessary for hematopoietic cell transformation. 
Materials and Methods 
Ba/F3 Cell Growth Assays. Ba/F3 cells expressing CALRMUT or MPL variants were generated 
by retroviral transduction and assayed for cytokine-independent growth as previously 
described (9). 
In Vitro Binding Assay. V5-tagged purified recombinant CALRWT, CALRMUT, CALRMUT- D135L 
and CALRMUT-D317A proteins were incubated with purified recombinant ERp57 or MPL for 30 
minutes at 4°C, and washed with HEPES-acetate buffer. Bound proteins were eluted fr om 
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beads and analyzed by SDS-PAGE. 
Results and Discussion 
To resolve which amino acids within the CALRMUT C-terminus are required for CALRMUT 
activity, we generated CALRMUT variants harboring serial truncations of the mutant C- terminal 
tail in blocks of 8-10 amino acids (Figure 1A) and tested their ability to associate with MPL in 
pull-down assays. All CALRMUT variants examined retained the ability to bind MPL (Figure 
1B). However, the most severely truncated form (CALRMUTA36) failed to activate JAK-STAT 
signaling (Figure 1C), stimulate phosphorylation of MPL (Figure ID), and transform Ba/F3-
MPL cells to IL-3 independence (Figure 1E). Further truncation of an 11 amino acid positively 
charged stretch (QRTRRMMRTKM) that is also present in CALRMUT protein species 
generated by the 52 bp deletion (CALRMUTA47, Supplemental Figure S1A) led to loss of 
MPL binding (Supplemental Figure S1B) and inability to transform Ba/F3-MPL cells 
(Supplemental Figure S1C). A CALRMUT variant where these 11 residues are deleted but the 
distal 36 mutant-specific amino acids are retained (CALRMUTA37-47) was still able to bind to 
MPL and transform Ba/F3-MPL cells (Supplemental Figure S1A-C), suggesting that the 
QRTRRMMRTKM stretch is sufficient but not strictly required for MPL binding. Our data also 
suggest that whilst CALRMUTA36 can bind to MPL, this binding is insufficient to activate MPL 
signaling. To our knowledge, these data provide the first evidence that physical interaction 
between CALRMUT and MPL is not ipso facto sufficient to activate MPL. Rather, our data 
argue for a model whereby different thresholds of positive charge in the CALRMUT C-terminus 
are required to enable binding of CALRMUT to MPL and to activate MPL signaling. As MPL 
phosphorylation is dependent on homodimerization of single MPL chains, these data may 
suggest that CALRMUTA36 retains the ability to interact with single MPL chains but is unable to 
induce homodimerization which is required for receptor activation. Further studies are 
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warranted to fully resolve the threedimensional structure of the CALRMUT-MPL interaction. 
We next sought to elucidate the regions of MPL that are essential to support CALRMUT activity. 
We observed that CALRMUT binds to full length MPL and to the extracellular and 
transmembrane (EC+TM) fragment of MPL, but not to the intracellular and transmembrane 
(IC+TM) fragment (Figure 1F). Furthermore, a MPL variant where the thrombopoietin (TPO) 
binding site is mutated (D235A/L239A) (11) was still able to bind to CALRMUT (Supplemental 
Figure S1D) and could support CALRMUT-mediated cytokine-independent growth in Ba/F3 
cells (Supplemental Figure S1E). This suggests that CALRMUT does not occupy the same 
binding pocket as TPO and is consistent with CALRMUT-driven hematopoietic transformation 
being a TPO-independent process (7). 
Analysis of the intracellular portion of MPL reveals three tyrosine residues (Y591, Y626 and 
Y631) which may also be important for CALRMUT-MPL signaling (12). MPL variants were 
therefore generated where these residues were systematically mutated to phenylalanine 
individually (FYY, YFY, YYF), in tandem (FFY, FYF, YFF) or altogether (FFF). As expected, 
all MPL variants were able to physically interact with CALRMUT in FLAG-pull down assays 
(Figure 1G). However, we found differences in their ability to support CALRMUT signaling. MPL 
variants harboring intact Y626 (MPL-FYY, MPL-YYF, MPL-FYF) supported robust Stat5 
phosphorylation (Figure 1H) in association with cytokine-independent growth (Figure 1I), but 
not MPL variants in which the Y626 is mutated (MPL-YFY, MPL-YFF, MPL-FFY, MPL-FFF). 
These data indicate that Y626 plays a more prominent role than Y591 and Y631 in MPL 
signaling downstream of CALRMUT, which is consistent with a previous report identifying Y626 
as the major signaling tyrosine in canonical TPO-MPL signaling (12). Our data therefore 
highlight the importance of tyrosine-mediated MPL signaling as a pathway co-opted by 
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CALRMUT to effect cytokine-independent proliferation. Our studies do not rule out a role for 
nontyrosine residues of MPL, which may be required for CALRMUT-mediated activation of 
other downstream signaling pathways (e.g. ERK) (13) and future studies to explore this 
question are warranted. 
Finally, we sought to gain functional insights into how CALRMUT interacts with MPL to confer 
cytokine independent growth. Wild-type calreticulin is an ER-resident chaperone that interacts 
with glycoproteins by binding to Glc1Man9GlcNAc2 oligosaccharides and the polypeptide 
backbone to facilitate proper protein folding. We therefore created variants of CALRMUT 
harboring mutations in critical residues implicated in three key functionalities of wild-type 
CALR - (i) polypeptide binding, (ii) chaperone activity, and (iii) lectin activity - and tested their 
capacity to bind to MPL and confer cytokine- independence (Figure 2A). 
We observed that both polypeptide binding-deficient variants of CALRMUT (CALRMUT- 
P19K/V21E and CALRMUT-W244G) and chaperone-deficient variants of CALRMUT (CALRMUT-
H153G and CALRMUT-EEDE) (14-15) retained MPL binding ability (Figure 2B) and conferred 
cytokine-independent growth (Figure 2C). Consistent with the nonessentiality of chaperone 
functionality in CALRMUT oncogenic activity, CALRWT exhibits strong, direct binding to the 
ERp57 co-chaperone, whereas CALRMUT does not (Figure 2D). In contrast, lectin-deficient 
CALRMUT variants harboring mutations in Asp-135 and Asp-317 (CALRMUT-D135L and 
CALRMUT-D317A) (16-17) were both unable to bind to MPL or confer cytokine independence 
(Figure 2B-C). In accordance, we also found that only recombinant CALRMUT protein directly 
binds to recombinant MPL in an in vitro binding assay, whereas neither CALRWT nor lectin-
deficient CALRMUT bind (Figure 2E).These data explain the previously reported essential role 
for Asp-135 in mediating CALRMUT-driven STAT5 activation (8) as being due to a requirement 
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for Asp-135 in mediating binding between CALRMUT to MPL. Finally, to determine the requisite 
glycosylation status of MPL that enables CALRMUT binding, we tested CALRMUT binding to 
MPL mutants where either two (2xNQ = N117/178Q) or all four (4xNQ = N117/178/298/358Q) 
glycosylation sites in the extra-cellular domain of MPL were abolished. We found that 
CALRMUT can still bind to MPL-2xNQ but not to MPL-4xNQ (Figure 2F). These data are 
consistent with a previous report which demonstrated that MPL variants devoid of the same 
four N-glycosylation sites failed to support STAT5 activation by CALRMUT (8), and suggests 
that this defect is due to an inability of unglycosylated MPL to bind CALRMUT. 
In conclusion, our data provide additional insights into the molecular mechanism by which 
CALRMUT interacts with MPL to induce MPN (Supplemental Table 1). Specifically, we (i) 
uncouple the binding of CALRMUT to MPL from MPL activation, (ii) define the key properties of 
MPL required for CALRMUT binding and for its activation and (iii) decipher the key 
functionalities of CALRMUT required for its oncogenic activity. 
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Figure Legends 
Figure 1. Binding of mutant calreticulin to MPL is required to transform hematopoietic 
cells but binding alone is insufficient for cytokine independent growth (A) Schema 
depicting serial C-terminal truncation mutants of mutant CALR. (B) Immunoblotting of FLAG 
immunoprecipitated proteins and whole cell lysates from 293T cells co-transfected with FLAG-
CALR wild type (CALRWT), FLAG-CALR 52 bp deletion (CALRmut), or FLAG-CALR 52 bp 
deletion serial C-terminal truncation mutants (CALRMUT A10-A36) demonstrates that mutant 
CALR truncated up to A36 still binds to MPL. (C) Immunblotting demonstrates 
phosphorylation of Stat5 and Stat3 in Ba/F3-MPL cells expressing CALRMUT and truncation 
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variants A10, A18, and A28, but not A36. (D) Immunoblotting demonstrates phosphorylation 
of MPL in Ba/F3-MPL cells expressing CALRMUT and A28, but not A36. (E) Growth curves in 
Ba/F3-MPL cells expressing CALRwt, CALRmut, or CALRMUT C-terminal truncation variants 
demonstrates that only severe truncation of the mutant CALR C-terminus (A36) abolishes the 
transforming capacity of mutant CALR. (F) Immunoblotting of FLAG immunoprecipitated 
proteins from 293T cells co-transfected with FLAG-CALR 52 bp deletion (CALRMUT) and GST-
tagged full length MPL, GST-tagged MPL intracellular + transmembrane domains (IC+TM), or 
GST-tagged MPL extracellular + transmembrane domains (EC+TM) demonstrates that 
mutant CALR binds to the extracellular domain of MPL. (G) Immunoblotting of FLAG 
immunoprecipitated proteins from 293T cells co-expressing FLAG-tagged mutant CALR and 
MPL YF variants demonstrates that mutations of intracellular tyrosine residues on MPL does 
not affect the ability of mutant CALR to bind to MPL. (H) Immunoblotting demonstrates that 
phosphorylation of Stat5 is abrogated in Ba/F3 cells expressing MPL YF variants harboring 
loss of Y626. (I) Growth curves in Ba/F3 cells stably expressing MPL-YF variants 
demonstrates that all three intracellular tyrosines play a role in supporting cytokine 
independent growth in Ba/F3 cells mediated by mutant CALR. 
Figure 2. The lectin-dependent function of mutant CALR is required for cytokine 
independent growth while its chaperone and polypeptide binding functionalities are 
dispensable (A) Schema depicting mutations introduced into the lectin (dark red), 
polypeptide binding (blue), and chaperone (light green) domains of mutant CALR. (B) 
Immunoblotting of FLAG immunoprecipitated proteins from 293T cells co-transfected with wild 
type CALR, mutant CALR, or mutant CALR lectin-, chaperone- and polypeptide binding-
deficient variants demonstrates that binding between mutant CALR and MPL is lost when 
residues required for lectin binding are mutated but binding is retained when residues critical 
for CALR chaperone and polypeptide binding functionality are mutated. (C) Growth curves in 
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Ba/F3-MPL cells expressing wild type CALR, mutant CALR, or mutant CALR lectin- (left), 
chaperone- (middle) and polypeptide binding-deficient (right) variants demonstrates that 
mutant CALR loses its ability to drive cytokine independent growth when residues required for 
lectin binding are mutated but retains its ability to drive cytokine independent growth in when 
residues critical for CALR chaperone and polypeptide binding functionality are mutated. (D) In 
vitro binding assay between purified recombinant CALRWT or CALRMUT and purified 
recombinant ERp57 demonstrates that CALRWT binds directly to ERp57 but CALRMUT does 
not. (E) In vitro binding assay between purified recombinant CALRWT, CALRMUT, CALRMUT-
D135L or CALRMUT-D317A demonstrates that CALRMUT binds directly to MPL but not CALRWT 
or altered CALRMUT variants. (F) FLAG pulldown in 293T cells co-expressing CALRMUT and 
MPL glycoslylation mutants (2xNQ = N117/178Q; 4xNQ = N117/178/298/358Q), shows 
CALRMUT binding to MPL-2xNQ but not to MPL-4xNQ. 


